Skip to main content
Premium Trial:

Request an Annual Quote

TorreyPines, Eisai Extend Genetic Research Collaboration for Alzheimer's

NEW YORK (GenomeWeb) - TorreyPines Therapeutics and Eisai have extended an agreement to identify and validate genes that may be used as targets for Alzheimer's drug compounds, TorreyPines said yesterday.
 
The research collaboration, which the companies began in 2005, is using whole-genome family-based association screening to identify genes associated with Alzheimer's disease.
 
TorreyPines, based in La Jolla, Calif., will receive an upfront payment and funding for the research for another year, and Eisai will have exclusive rights for first negotiation and refusal for gene targets that come from the research.
 
TorreyPines said the companies also are involved in a separate agreement to find novel compounds that may be used to treat Alzheimer's disease.
 
Financial terms of the agreement were not released.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.